OKYO Pharma Announces $5.84 Million Cash Raise and Payables Reduction Pricing of a registered direct offering for $1.64M of 1,092,600...
OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”) OKYO plans...
OKYO Pharma Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease ("DED"...
OKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary Shares LONDON and NEW YORK, Sept. 15, 2023 (GLOBE...
OKYO Pharma Announces Pricing of $4.0 Million Registered Direct Offering of Ordinary Shares LONDON and NEW YORK, Sept. 14, 2023 (GLOBE...
OKYO Pharma Limited Announces Withdrawal of Public Offering LONDON and NEW YORK, Sept. 14, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited...
OKYO Pharma Announces Public Offering of Ordinary Shares LONDON and NEW YORK, Sept. 13, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited...
OKYO Pharma Completes Enrollment in Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease Full enrollment achieved on September 6th with...
Full enrollment anticipated by first week of SeptemberOKYO on schedule to release top-line data before end of...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.